1,254
Views
16
CrossRef citations to date
0
Altmetric
Diabetes: Original Article

Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1c value

, , , , , , & show all
Pages 1281-1287 | Accepted 08 Jun 2012, Published online: 06 Jul 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Valentina Lorenzoni, Fabio Baccetti, Stefano Genovese, Enrico Torre & Giuseppe Turchetti. (2017) Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research 9, pages 699-710.
Read now
Shengsheng Yu, Alex Z. Fu, Samuel S. Engel, R. Ravi Shankar & Larry Radican. (2016) Association between hypoglycemia risk and hemoglobin A1C in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 32:8, pages 1409-1416.
Read now
Bruno Detournay, Serge Halimi, Julien Robert, Céline Deschaseaux & Sylvie Dejager. (2015) Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vascular Health and Risk Management 11, pages 417-425.
Read now
A.H. Barnett, R. Brice, W. Hanif, J. James & H. Langerman. (2013) Increasing awareness of hypoglycaemia in patients with Type 2 diabetes treated with oral agents. Current Medical Research and Opinion 29:11, pages 1503-1513.
Read now

Articles from other publishers (12)

Jürgen Wernecke. (2023) Behandlung von alten Menschen mit Typ-2-DiabetesTreatment of elderly type 2 diabetes patients. Die Diabetologie 19:7, pages 827-834.
Crossref
Callum Howard, Leonardo Picca, Tristan Smith, Monira Sharif, Mohamad Bashir & Amer Harky. (2019) The bicuspid aortic valve: Is it an immunological disease process?. Journal of Cardiac Surgery 34:6, pages 482-494.
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria-Inti Metzendorf, Bernd Richter & Bianca Hemmingsen. (2019) Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Michael Nauck, Atsushi Araki, Uwe Hehnke, Arian Plat, Douglas Clark & Kamlesh Khunti. (2018) Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. International Journal of Clinical Practice 72:10, pages e13240.
Crossref
Huai Heng Loh, Anne Yee, Huai Seng Loh, Norlela Sukor & Nor Azmi Kamaruddin. (2016) Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis. Primary Care Diabetes 10:3, pages 210-219.
Crossref
C. F. Deacon & H. E. Lebovitz. (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 18:4, pages 333-347.
Crossref
Juliana C.N. Chan, Pablo Aschner, David R. Owens, Sylvie Picard, Maya Vincent, Marie-Paule Dain, Valerie Pilorget, Virginie Loizeau, Akram Echtay & Vivian Fonseca. (2015) Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: The EASIE post-hoc analysis and extension trial. Journal of Diabetes and its Complications 29:1, pages 134-141.
Crossref
Bo Ahrén, James Edward Foley, Sylvie Dejager, Mouna Akacha, Qing Shao, Guenter Heimann, Markus Dworak & Anja Schweizer. (2014) Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?. Diabetes Therapy 5:2, pages 459-469.
Crossref
Jamie R. Wood & Janet Silverstein. (2013) Incretins and amylin in pediatric diabetes. Current Opinion in Pediatrics 25:4, pages 502-508.
Crossref
Baptist Gallwitz. (2013) Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes. Diabetes Management 3:4, pages 323-331.
Crossref
B. Gallwitz. (2013) Inkretinbasierte TherapienIncretin-based therapies. Der Diabetologe 9:4, pages 283-288.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.